...
机译:P2.05-030 WBRT先前EGFR TKI是NSCLC患者患EGFR突变的CNS转移的NSCLC患者的有效治疗选择
Pneumonology Oncology and Allergology Medical University of Lublin;
Pneumonology Oncology and Allergology Medical University of Lublin;
Department of Lung Cancer and Chest Tumors;
Department of Oncology;
Department of Lung Cancer and Chest Tumors;
Department of Oncology;
Institute of Genetics and Immunology Genim Ltd;
Pneumonology Oncology and Allergology Medical University of Lublin;
Pneumonology Oncology and Allergology Medical University of Lublin;
Department of Lung Cancer and Chest Tumors;
机译:P2.05-030 WBRT先前EGFR TKI是NSCLC患者患EGFR突变的CNS转移的NSCLC患者的有效治疗选择
机译:EGFR TKIS Plus WBRT在NSCLC和EGFR突变和脑转移患者中,除了TKIS之外,除了TKIS之外的生存益处也没有。
机译:与单独使用TKIS相比,中医结合EGFR-TKI延长了无小细胞肺癌(NSCLC)患者的无流动存活和整体存活率
机译:单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
机译:EGFR-TKIs在非小细胞肺癌治疗中的有效性:一项荟萃分析。
机译:WBRT + EGFR-TKIs与单独使用WBRT或TKIs治疗脑转移性NSCLC患者的临床结局:荟萃分析
机译:P2.05-030 WBRT先前EGFR TKI是NSCLC患者患EGFR突变的CNS转移的NSCLC患者的有效治疗选择